Grundlæggende statistik
| CIK | 1473579 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Nanomix Corporation
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| November 8, 2024 |
NNMX / Nanomix Corporation / Hudson Bay Capital Management LP - NNMX 13G/A Passive Investment SC 13G/A 1 nnmx13ga.htm NNMX 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Nanomix Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 63008H201 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| February 6, 2024 |
NNMX / Nanomix Corporation / Hudson Bay Capital Management LP - NNMX 13GA Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Nanomix Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 63008H201 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| November 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 NANOMIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or other jurisdiction (Commission File Number) (I. |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Perio |
|
| April 7, 2023 |
Description of Securities of Nanomix Corporation Exhibit 4.27 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2022 Nanomix Corporation had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). References herein to “we,” “us,” “our” and the “Company” refer to Nanomix Corporation and not to a |
|
| April 7, 2023 |
Exhibit 21.1 List of Subsidiaries All subsidiaries are wholly owned except where otherwise indicated. Name Jurisdiction of Organization Nanomix, Inc. California CurDM Group Holdings LLC Delaware |
|
| April 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54586 NANOMIX CORPORATION (Exac |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Per |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 NANOMIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or other jurisdiction (Commission (I. |
|
| February 10, 2023 |
NNMX / Nanomix Corp / Hudson Bay Capital Management LP - NNMX 13GA Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Nanomix Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 63008H201 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| January 25, 2023 |
Nanomix Appoints Finance Veteran Chris Hetterly as Chief Financial Officer Exhibit 99.1 Nanomix Appoints Finance Veteran Chris Hetterly as Chief Financial Officer SAN LEANDRO, Calif. (January 25, 2023) – Nanomix Corporation (OTCQB: NNMX) (“Nanomix” or the “Company”), a leader in mobile, affordable, point-of-care (POC) diagnostics, today announced the appointment of Christopher R. Hetterly as Chief Financial Officer (CFO). Mr. Hetterly is a financial executive and entrepr |
|
| January 25, 2023 |
Offer Letter for Chris Hetterly, dated November 15, 2022 Exhibit 10.1 November 15, 2022 Christopher R, Hetterly Palo Alto, CA Via Email - [email protected] Dear Chris, We are pleased to offer you the position of CHIEF FINANCIAL OFFICER of Nanomix Corporation (the “Company”). As Nanomix Chief Financial Officer, you will be responsible for all financial aspects of the Nanomix business. Your compensation will include a salary of $270,000 on an annual ba |
|
| January 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2023 NANOMIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or other jurisdiction (Commission File Number) (I. |
|
| November 14, 2022 |
United states SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ quarterly report under section 13 0r 15(d) of the securities exchange act of 1934 For the quarterly period ended September 30, 2022 ☐ transition report under section 13 0r 15(d) of the securities exchange act of 1934 For the transition period from to Commission file number 000-54586 NANOMIX CORPORATION ( |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2022 NANOMIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or other jurisdiction of incorporation) (Commission File Number) (I. |
|
| November 10, 2022 |
Subscription Agreement, dated October 21, 2022, by and between the Company and the Investor Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of October 21, 2022, between Nanomix Corporation, a Delaware corporation (the ?Company?), and the purchasers set forth on the signature pages affixed hereto (each, a ?Purchaser? and, collectively, the ?Purchasers?). WHEREAS, subject to the terms and conditions set forth in this Agreement an |
|
| November 10, 2022 |
Exhibit 99.1 Nanomix Enters into an Exclusive Veterinary Distribution Agreement for the eLab System with Woodley Equipment Company, Ltd. SAN LEANDRO, Calif. (November 9, 2022) ? Nanomix Corporation (OTCQB: NNMX) (?Nanomix? or the ?Company?), a leader in the development of mobile, affordable, point-of-care (POC) diagnostics, today announced that it has entered into an exclusive distribution agreeme |
|
| September 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2022 NANOMIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or other jurisdiction (Commission File Number) (I. |
|
| September 9, 2022 |
Nanomix Appoints Industry Veteran Tadd S. Lazarus, M.D., to the Board of Directors Exhibit 99.1 Nanomix Appoints Industry Veteran Tadd S. Lazarus, M.D., to the Board of Directors SAN LEANDRO, Calif. (August 31, 2022) ? Nanomix Corporation (OTCQB: NNMX) (?Nanomix? or the ?Company?), a leader in the development of mobile, affordable, point-of-care diagnostics, today announced the appointment of Tadd S. Lazarus, M.D., to the Board of Directors as an independent director. ?We are ex |
|
| August 15, 2022 |
United states SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? quarterly report under section 13 0r 15(d) of the securities exchange act of 1934 For the quarterly period ended June 30, 2022 ? transition report under section 13 0r 15(d) of the securities exchange act of 1934 For the transition period from to Commission file number 000-54586 NANOMIX CORPORATION (Exact |
|
| July 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2022 NANOMIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or other jurisdiction (Commission File Number) (I. |
|
| July 29, 2022 |
Offer Letter, dated July 21, 2022 Exhibit 10.1 July 21, 2022 Mr. Thomas Schlumpberger Via Email Dear Thomas, We are very excited to offer you the position of CEO for Nanomix Corporation. As Nanomix Chief Executive Officer, you will report to the Board of Directors and be responsible for all aspects of the Nanomix business. You will also be appointed a member of the Board of Directors. Your compensation will include an annual salar |
|
| July 29, 2022 |
Exhibit 99.1 Nanomix Announces Appoints Life Sciences Executive Thomas Schlumpberger as Chief Executive Officer and Member of the Board of Directors SAN LEANDRO, Calif., July 26, 2022 (GLOBE NEWSWIRE) - Nanomix Corporation (OTCQB: NNMX) (?Nanomix? or the ?Company?), a leader in mobile, affordable, point-of-care diagnostics, today announced the appointment of Dr. Thomas Schlumpberger as Chief Execu |
|
| July 13, 2022 |
NANOMIX CORP. 19,507,630 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-265744 NANOMIX CORP. 19,507,630 Shares of Common Stock This prospectus relates to the sale from time to time of up to 19,507,630 shares of common stock held by the selling stockholders named in this prospectus, including (i) up to 7,500,000 shares of common stock issuable upon conversion of outstanding series D convertible preferred stock, or t |
|
| July 6, 2022 |
Nanomix Corporation 2121 Williams Street San Leandro, CA 94577 Nanomix Corporation 2121 Williams Street San Leandro, CA 94577 July 6, 2022 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N. |
|
| July 6, 2022 |
As filed with the Securities and Exchange Commission on July 6, 2022 As filed with the Securities and Exchange Commission on July 6, 2022 Registration Statement No. |
|
| July 6, 2022 |
Form of Warrant assumed as part of the Nanomix Merger Exhibit 4.28 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS IN ACCORDANCE WITH APPLICABLE REGISTRATION REQUIREMENTS |
|
| June 21, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Nanomix Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be paid Equity Common Stock, par value $0. |
|
| June 21, 2022 |
As filed with the Securities and Exchange Commission on June 21, 2022 As filed with the Securities and Exchange Commission on June 21, 2022 Registration Statement No. |
|
| May 17, 2022 |
NANOMIX CORP. 28,801,837 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-260298 PROSPECTUS NANOMIX CORP. 28,801,837 Shares of Common Stock This prospectus relates to the sale from time to time of up to 28,801,837 shares of common stock held by the selling stockholders named in this prospectus, including up to 14,400,918 shares of common stock issuable upon conversion of outstanding senior secured convertible promiss |
|
| May 17, 2022 |
United states SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? quarterly report under section 13 0r 15(d) of the securities exchange act of 1934 For the quarterly period ended March 31, 2022 ? transition report under section 13 0r 15(d) of the securities exchange act of 1934 For the transition period from to Commission file number 000-54586 NANOMIX CORPORATION (Exac |
|
| May 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-CEN ? Form N-CSR For Period Ended: March 31, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q For the Transition Perio |
|
| May 10, 2022 |
Offer Letter, dated February 28, 2022 Exhibit 10.1 |
|
| May 10, 2022 |
Nanomix Corporation 2121 Williams Street San Leandro, CA 94577 CORRESP 1 filename1.htm Nanomix Corporation 2121 Williams Street San Leandro, CA 94577 May 10, 2022 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Margaret Schwartz Re: Nanomix Corporation Registration Statement on Form S-1 File No. 333-260298 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the S |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2022 NANOMIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or other jurisdiction (Commission File Number) (I. |
|
| May 10, 2022 |
Exhibit 99.1 Nanomix Appoints Vidur Sahney as Chief Operating Officer Relocates Headquarters and Labs to a Larger Facility while Reducing Overhead Expense SAN LEANDRO, Calif.-(BUSINESS WIRE)- Nanomix Corporation (OTCBB: NNMX, NNMXD), a leader in the development of mobile, affordable, point-of-care diagnostics, announces the appointment of Vidur Sahney as Chief Operating Officer. Mr. Sahney brings |
|
| May 9, 2022 |
As filed with the Securities and Exchange Commission on May 9, 2022 As filed with the Securities and Exchange Commission on May 9, 2022 Registration Statement No. |
|
| May 9, 2022 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-1 (Form Type) Nanomix Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be paid Equ |
|
| April 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54586 NANOMIX CORPORATION (Exac |
|
| April 12, 2022 |
Description of Securities of Nanomix Corporation Exhibit 4.27 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2021 Nanomix Corporation had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). References herein to ?we,? ?us,? ?our? and the ?Company? refer to Nanomix Corporation and not to a |
|
| April 12, 2022 |
Exhibit 10.23 Certain information in this document (indicated by ?[***]?) has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. EXECUTION VERSION DEVELOPMENT AND LICENSE AGREEMENT This Development and License Agreement (?Agreement?) is entered into as of this 26th day |
|
| April 12, 2022 |
Exhibit 10.24 Certain information in this document (indicated by ?[***]?) has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. Certain portions of this exhibit (indicated by ?####?) have been omitted pursuant to Regulation S-K, Item 601(a)(6). FIRST AMENDMENT TO DEVE |
|
| April 12, 2022 |
Exhibit 21.1 List of Subsidiaries All subsidiaries are wholly owned except where otherwise indicated. Name Jurisdiction of Organization Nanomix, Inc. California CurDM Group Holdings LLC Delaware |
|
| March 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2021 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Pe |
|
| March 24, 2022 |
Exhibit 10.2 CONSENT, AMENDMENT AND WAIVER This CONSENT, AMENDMENT AND WAIVER (this ?Consent?) is made and entered into as of March 22, 2022 by and among Nanomix Corporation, a Delaware corporation (which was formerly known as Boston Therapeutics, Inc.) (the ?Company?) and HT Investments MA LLC (the ?Investor?). WHEREAS, pursuant to a Securities Purchase Agreement, dated as of June 25, 2021 (as am |
|
| March 24, 2022 |
Form of Warrant, dated March 23, 2022 Exhibit 4.1 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND, ACCORDINGLY, MAY NOT BE TRANSFERRED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, |
|
| March 24, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of March [ ], 2022, between NANOMIX CORPORATION, a Delaware corporation (the ?Company?), and the purchaser identified on the signature page hereto (including its successors and assigns, the ?Purchaser?). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant t |
|
| March 24, 2022 |
Exhibit 3.1 NANOMIX CORPORATION CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES D CONVERTIBLE PREFERRED STOCK The undersigned, David Ludvigson, does hereby certify that: 1. He is the Chief Executive Officer, of Nanomix Corporation, a Delaware corporation (the ?Corporation? or the ?Company?). 2. The Corporation is authorized to issue up to 5,000,000 shares of preferred s |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2022 NANOMIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or other jurisdiction (Commission (I. |
|
| March 2, 2022 |
Nanomix Completes 1-for-173 Reverse Stock Split Exhibit 99.1 Nanomix Completes 1-for-173 Reverse Stock Split EMERYVILLE, Calif. (March 2, 2022) ? Nanomix Corporation (OTCBB: NNMX) (?Nanomix? or the ?Company?), a leader in the development of mobile, affordable, point-of-care diagnostics, today announced it has completed the previously announced reverse stock split of its outstanding shares of common stock at a ratio of 1-for-173. The reverse sto |
|
| March 2, 2022 |
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2022 NANOMIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or other jurisdiction (Commission File Number) (I. |
|
| March 2, 2022 |
Exhibit 3.1 Delaware Page 1 The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF ?NANOMIX CORPORATION?, FILED IN THIS OFFICE ON THE ELEVENTH DAY OF JANUARY, A.D. 2022, AT 8:02 O`CLOCK A.M. 4722580 8100 Authentication: 202364177 SR# 20220085809 Date: 01-11-22 You may verify th |
|
| March 1, 2022 |
Exhibit 10.2 CONSENT, AMENDMENT AND WAIVER This CONSENT, AMENDMENT AND WAIVER (this ?Consent?) is made and entered into as of February 24, 2022 by and among Nanomix Corporation, a Delaware corporation (which was formerly known as Boston Therapeutics, Inc.) (the ?Company?) and HT Investments MA LLC (the ?Investor?). WHEREAS, pursuant to a Securities Purchase Agreement, dated as of June 25, 2021 (as |
|
| March 1, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of February 25, 2022, is by and among Nanomix Corporation, a Delaware corporation with offices located at 5900 Hollis Street, Suite P, Emeryville, CA 94608 (the ?Company?), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a ?Buyer? and collectively, the |
|
| March 1, 2022 |
Exhibit 4.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 NANOMIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or other jurisdiction (Commission File Number) (I. |
|
| March 1, 2022 |
Exhibit 4.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T |
|
| February 7, 2022 |
BTHE / Boston Therapeutics Inc / Hudson Bay Capital Management LP - NNMX 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Nanomix Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 63008H102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| November 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 15, 2021 NANOMIX CORPORATION (Exact name of registrant as specified in its charter) BOSTON THERAPEUTICS, INC. (Former name or former address, if changed since last report.) D |
|
| November 15, 2021 |
United states SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? quarterly report under section 13 0r 15(d) of the securities exchange act of 1934 For the quarterly period ended September 30, 2021 ? transition report under section 13 0r 15(d) of the securities exchange act of 1934 For the transition period from to Commission file number 000-54586 NANOMIX CORPORATION ( |
|
| November 5, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2021 BOSTON THERAPEUTICS, INC. |
|
| November 5, 2021 |
Exhibit 99.7 RISK FACTORS An investment in our securities involves a high degree of risk. Before making an investment decision, you should give careful consideration to the following risk factors, in addition to the other information included herein, including our financial statements and related notes, before deciding whether to invest in our securities. The occurrence of any of the adverse devel |
|
| November 5, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2021 BOSTON THERAPEUTICS, INC. |
|
| November 5, 2021 |
Exhibit 99.6 BUSINESS Overview On June 6, 2021, we completed our merger, or the Merger, with Nanomix, Inc., a California corporation, or Nanomix. As consideration for the Merger, we issued to the shareholders of Nanomix 1,000,000 shares of a newly created Series C Convertible Preferred Stock of the Company (the ?Preferred Stock?). Upon the effectiveness of the amendment to our Certificate of Incor |
|
| November 5, 2021 |
EX-99.1 2 ea150028ex99-1boston.htm INVESTOR PRESENTATION, OCTOBER 2021 Exhibit 99.1 November 2021 Safe Harbor Statement Statements contained in this presentation that are not historical facts may be forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements include statements regarding the intent, belief or current expecta |
|
| October 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (Rule 14c-101) SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Information Statement ? Confidential, for Use of the Commis |
|
| October 15, 2021 |
As filed with the Securities and Exchange Commission on October 15, 2021 As filed with the Securities and Exchange Commission on October 15, 2021 Registration Statement No. |
|
| October 15, 2021 |
EX-3.5 2 ea148854ex3-5boston.htm CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF THE SERIES C PREFERRED STOCK Exhibit 3.5 State of Delaware Secretary of State Division of Corporations Delivered 05:22 PM 06/03/2021 FILED 05:22 PM 06/03/2021 SR 20212347456 - File Number 4722580 CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF THE SERIES C CONVERTIBLE PREFERRED STOCK OF BOSTON THERAPEUTI |
|
| October 5, 2021 |
United states SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? quarterly report under section 13 0r 15(d) of the securities exchange act of 1934 For the quarterly period ended June 30, 2021 ? transition report under section 13 0r 15(d) of the securities exchange act of 1934 For the transition period from to Commission file number 000-54586 BOSTON THERAPEUTICS, inc. |
|
| September 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 8, 2021 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Incorporation) (Commis |
|
| September 10, 2021 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF BOSTON THERAPEUTICS, INC. Boston Therapeutics, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?Corporation?), DOES HEREBY CERTIFY: 1. This Certificate of Amendment (the ?Certificate of Amendment?) amends the provisions of the Corporation?s Certificate of Incorpora |
|
| September 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (Rule 14c-101) SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Information Statement ? Confidential, for Use of the Commis |
|
| August 27, 2021 |
NANOMIX, INC. INDEX TO FINANCIAL STATEMENTS Exhibit 99.3 ITEM 8 ? FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA NANOMIX, INC. INDEX TO FINANCIAL STATEMENTS Report of Independent Registered Public Accounting Firm F-2 Balance Sheets as of December 31, 2020 and 2019 F-3 Statements of Operations for the Years Ended December 31, 2020 and 2019 F-4 Statements of Changes in Stockholders? Deficit for the Years Ended December 31, 2020 and 2019 F-5 Stat |
|
| August 27, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2021 BOSTON THERAPEUTICS, INC. |
|
| August 27, 2021 |
Unaudited Pro Forma Condensed Consolidated Financial Information Exhibit 99.5 Unaudited Pro Forma Condensed Consolidated Financial Information On January 26, 2021, Boston Therapeutics, Inc., a Delaware corporation (the ?Company?), BTHE Acquisition Inc., a California corporation and wholly-owned subsidiary of the Company (?Merger Sub?), and Nanomix, Inc., a California corporation (?Nanomix?), entered into an Agreement and Plan of Merger (the ?Merger Agreement?), |
|
| August 27, 2021 |
Exhibit 99.1 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FORWARD-LOOKING STATEMENTS This report, including exhibits that are being filed as part of this report, as well as other statements made by Nanomix, Inc. (?Nanomix?, the ?Company?, ?we?, ?us?, and ?our?), contain ?forward-looking statements? that include information relating to future events, future |
|
| August 27, 2021 |
Exhibit 99.2 Nanomix, Inc. MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FORWARD-LOOKING STATEMENTS This report, including exhibits that are being filed as part of this report, as well as other statements made by Nanomix, Inc. (?Nanomix?, the ?Company?, ?we?, ?us?, and ?our?), contain ?forward-looking statements? that include information relating to future e |
|
| August 27, 2021 |
NANOMIX, INC. INDEX TO FINANCIAL STATEMENTS Exhibit 99.4 NANOMIX, INC. INDEX TO FINANCIAL STATEMENTS Balance Sheets as of March 31, 2021 and December, 31 2020 F-2 Statements of Operations for the Periods Ended March 31, 2021 and 2020 F-3 Statements of Changes in Stockholders? Deficit for the Periods Ended March 31 2021 and 2020 F-4 Statements of Cash Flows for the Periods Ended March 31, 2021 and 2020 F-5 Notes to Financial Statements F-6 F |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-CEN ? Form N-CSR For Period Ended: June 30, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q For the Transition Period |
|
| July 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14F-1 Information Statement Pursuant to Section 14(f) of the Securities Exchange Act of 1934 and Rule 14f-1 Thereunder Commission file number 000-52218 BOSTON THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 27-0801073 (State or Other Jurisdiction of Incorporation or Organization) (I. |
|
| June 29, 2021 |
Exhibit 10.4 GUARANTY This GUARANTY, dated as of June 25, 2021 (this ?Guaranty?), is made by each of the undersigned (each a ?Guarantor?, and collectively, the ?Guarantors?), in favor of HT Investments MA LLC, a Delaware limited liability company, in its capacity as collateral agent (in such capacity, the ?Collateral Agent? as hereinafter further defined) for the ?Buyers? party to the Securities P |
|
| June 29, 2021 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of June 25, 2021, is by and among Boston Therapeutics, Inc., a Delaware corporation with offices located at 5900 Hollis Street, Suite P, Emeryville, CA 94608 (the ?Company?), and the undersigned buyers (each, a ?Buyer,? and collectively, the ?Buyers?). RECITALS A. In connection with the Secur |
|
| June 29, 2021 |
Exhibit 4.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T |
|
| June 29, 2021 |
Exhibit 10.5 EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT (the ?Agreement?) is made as of the day of June 2021, by and between, Boston Therapeutics, Inc., a Delaware corporation (the ?Company?), and (the ?Holder?). WHEREAS, the Holder holds a Secured Promissory Note in the principal note of $ (collectively, the ?Securities?). WHEREAS, subject to the satisfaction of the conditions set forth herein, t |
|
| June 29, 2021 |
Exhibit 10.3 Execution version SECURITY AND PLEDGE AGREEMENT SECURITY AND PLEDGE AGREEMENT, dated as of June 25, 2021 (this ?Agreement?), made by Boston Therapeutics, Inc., a Delaware corporation with offices located at 354 Merrimack Street #4, Lawrence, MA 01843 (the ?Company?), and each of the undersigned direct and indirect Domestic Subsidiaries of the Company from time to time, if any (each a |
|
| June 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2021 BOSTON THERAPEUTICS, INC. |
|
| June 29, 2021 |
Exhibit 4.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T |
|
| June 29, 2021 |
Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of June 25, 2021, is by and among Boston Therapeutics, Inc., a Delaware corporation with offices located at 5900 Hollis Street, Suite P, Emeryville, CA 94608 (the ?Company?), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a ?Buyer? a |
|
| June 29, 2021 |
Exhibit 99.1 Boston Therapeutics Announces $8.4 Million Convertible Placement in Conjunction with Nanomix Reverse Merger EMERYVILLE, Calif., June 29, 2021 ? Boston Therapeutics, Inc. (the ?Company?) (OTCQB:BTHE) and merger partner Nanomix, Inc. (?Nanomix?), a leader in the development of mobile, affordable, point-of-care diagnostics, today announced that it has entered into a securities purchase a |
|
| June 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54586 BOSTON THERAPEUTICS, |
|
| June 10, 2021 |
8-K 1 ea142545-8kbostonthera.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2021 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or other jur |
|
| May 17, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 000-54586 NOTIFICATION OF LATE FILING (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form N-SAR ? Form N-CAR For Period Ended: March 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Repo |
|
| May 12, 2021 |
Exhibit 4.1 SECURED PROMISSORY NOTE $500,000 April 30, 2021 Payment of Principal and Interest. FOR VALUE RECEIVED, Boston Therapeutics, Inc., a Delaware corporation (?Maker?), hereby promises to pay to the order of [Gold Blaze Limited Vistra Corporate Services] (?Lender?), in the manner hereinafter provided, the principal amount of FIVE HUNDRED THOUSAND DOLLARS AND ZERO CENTS ($500,000.00) (the ?P |
|
| May 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 30, 2021 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 12, 2021 |
Exhibit 10.1 THE SECURITY REPRESENTED HEREBY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR ANY STATE SECURITIES LAWS AND NEITHER SUCH SECURITY NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT OR SUCH LAWS OR AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT AND SUCH LAWS WHIC |
|
| April 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54586 BOSTON THERAPEUTICS, INC. |
|
| April 5, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 000-54586 NOTIFICATION OF LATE FILING (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form N-SAR ? Form N-CAR For Period Ended: December 31, 2020 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition R |
|
| February 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2021 BOSTON THERAPEUTICS, INC. |
|
| February 2, 2021 |
EX-10.2 5 ea134438ex10-2boston.htm FORM OF DEBT SETTLEMENT AND RELEASE AGREEMENT Exhibit 10.2 DEBT SETTLEMENT AGREEMENT AND RELEASE THIS DEBT SETTLEMENT AGREEMENT AND RELEASE (this “Agreement”) is made and entered into as of January 25, 2021 (the “Effective Date”), by and between (the “Creditor”) and Boston Therapeutics, Inc., a Delaware corporation (the "Company"). RECITALS: WHEREAS, the Creditor |
|
| February 2, 2021 |
EX-10.1 4 ea134438ex10-1boston.htm FORM OF EXCHANGE AGREEMENT Exhibit 10.1 EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT (the “Agreement”) is made as of the day of 2021, by and between, Boston Therapeutics, Inc., a Delaware corporation (the “Company”), and (the “Holder”). WHEREAS, the Holder holds (collectively, the “Securities”). WHEREAS, subject to the satisfaction of the conditions set forth herei |
|
| February 2, 2021 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of February 2, 2021, is entered into by and among BOSTON THERAPEUTICS, INC., a Delaware corporation (“Public Company”); BTHE Acquisition Inc., a California corporation and a wholly owned subsidiary of Public Company (the “Merger Sub”); and NANOMIX, INC., a California corporation (“Merger Partner |
|
| February 2, 2021 |
Exhibit 4.1 CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF THE SERIES B CONVERTIBLE PREFERRED STOCK OF BOSTON THERAPEUTICS, INC. The undersigned, Conroy Chi-Heng Cheng, President and Chief Executive Officer of Boston Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under the Delaware General Corporation Law (the “DGCL”), hereby does certify: That pursuant to the |
|
| December 28, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54586 BOSTON THERAPEUT |
|
| December 17, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54586 BOSTON THERAPEUTICS, |
|
| November 30, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54586 BOSTON THERAPEUTICS, |
|
| June 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54586 BOSTON THERAPEUTICS, INC. |
|
| May 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2020 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 15, 2020 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 000-54586 NOTIFICATION OF LATE FILING (Amendment No. 1) (Check One): ☒ Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form N-SAR ¨ Form N-CAR For Period Ended: December 31, 2019 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 1 |
|
| May 11, 2020 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Registration No. 333-185355 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0801073 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification Number) |
|
| May 11, 2020 |
- POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Registration No. 333-195341 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0801073 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification Number) |
|
| May 11, 2020 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Registration No. 333-177171 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0801073 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification Number) |
|
| April 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 14, 2020 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 30, 2020 |
BTHE / Boston Therapeutics Inc NT 10-K - - NOTIFICATION OF LATE FILING SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 000-54586 NOTIFICATION OF LATE FILING (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form N-SAR ☐ Form N-CAR For Period Ended: December 31, 2019 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition R |
|
| January 23, 2020 |
Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 10, 2020 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 12, 2019 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 6, 2019 |
Letter from Liggett & Webb P.A. Exhibit 16.1 December 5, 2019 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated December 5, 2019 of Boston Therapeutics, Inc. (the “Company”) and agree with the statements relating only to Liggett & Webb, P.A. contained therein. We have no basis to agree or disagree with other statements of the Company contai |
|
| December 6, 2019 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 2, 2019 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 19, 2019 |
BTHE / Boston Therapeutics Inc 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54586 BOSTON THERAPEUT |
|
| November 15, 2019 |
BTHE / Boston Therapeutics Inc NT 10-Q - - NOTIFICATION OF LATE FILING SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 000-54586 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-SAR ☐ Form N-CAR For Period Ended: September 30, 2019 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition |
|
| September 25, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 24, 2019 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 19, 2019 |
BTHE / Boston Therapeutics Inc 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54586 BOSTON THERAPEUTICS, |
|
| August 19, 2019 |
Exhibit 10.1 UNWIND AGREEMENT THIS UNWIND AGREEMENT (this “Unwind Agreement”) is made effective as of the [] day of July, 2019 by and between Boston Therapeutics, Inc., a Delaware corporation (“BTHE”), CureDM, Inc., a Delaware corporation (“CureDM”), and CureDM Group Holdings, LLC, a Delaware limited liability company (“PriveCo”). RECITALS A. On February 12, 2018, BTHE entered into a Contribution |
|
| August 14, 2019 |
BTHE / Boston Therapeutics Inc NT 10-Q - - NOTIFICATION OF LATE FILING SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 000-54586 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-SAR ☐ Form N-CAR For Period Ended: June 30, 2019 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Repor |
|
| May 20, 2019 |
BTHE / Boston Therapeutics Inc 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54586 BOSTON THERAPEUTICS, |
|
| May 15, 2019 |
BTHE / Boston Therapeutics Inc NT 10-Q NT 10-Q SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 000-54586 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-SAR ☐ Form N-CAR For Period Ended: March 31, 2019 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Repo |
|
| April 16, 2019 |
BTHE / Boston Therapeutics Inc FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54586 BOSTON THERAPEUTICS, INC. |
|
| April 1, 2019 |
BTHE / Boston Therapeutics Inc NT 10-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 000-54586 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form N-SAR ☐ Form N-CAR For Period Ended: December 31, 2018 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition R |
|
| December 6, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 30, 2018 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 14, 2018 |
BTHE / Boston Therapeutics Inc 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54586 BOSTON THERAPEUT |
|
| August 14, 2018 |
BTHE / Boston Therapeutics Inc FORM 10Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54586 BOSTON THERAPEUTICS, |
|
| July 2, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 26, 2018 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 2, 2018 |
Exhibit 10.1 LICENSE AGREEMENT THIS LICENSE AGREEMENT (“Agreement”) is made and entered into as of this 26th day of June, 2018 (the “Effective Date”), by and between Level Brands, Inc., a North Carolina corporation, its subsidiary Level H & W, LLC a North Carolina limited liability company, together (“Licensor”), and Boston Therapeutics, Inc., a Delaware corporation (“Licensee”). Licensor and Lice |
|
| June 14, 2018 |
Exhibit 4.1 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAW, AND IT MAY NOT BE SOLD OR OTHERWISE TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER SAID ACT OR STATE LAW OR AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENTS; AND THE COMPANY MAY REQUIRE AN OPINION OF COUNSEL AS TO THE AVAILABILITY OF SUCH EXEMPTION. BOST |
|
| June 14, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 12, 2018 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 1, 2018 |
Exhibit 99.1 TRANSFORMING METABOLIC DISEASES CARL W. RAUSCH, CEO | LORAINE V. UPHAM, COO June 2018 Confidential and Proprietary 1 OTCQB:BTHE Boston Therapeutics We are a BioPharmaceutical company with technology and treatments to prevent or reverse diabetes and its complications. WHO WE ARE Confidential and Proprietary 2 GLYCO CHEMISTRY BTI - 320 SUGARDOWN ® PEPTIDE CHEMISTRY BTI - 410 Safe Harbor |
|
| June 1, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 1, 2018 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 14, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54586 BOSTON THERAPEUTICS, |
|
| April 30, 2018 |
Exhibit 99-1 CUREDM GROUP HOLDINGS, LLC FINANCIAL STATEMENTS YEARS ENDED DECEMBER 31, 2017 AND 2016 INDEX TO FINANCIAL STATEMENTS Report of Independent Registered Public Accounting Firm 2 Balance Sheets as of December 31, 2017 and 2016 3 Statements of Operations and Members’ Equity for the years ended December 31, 2017 and 2016 4 Statements of Cash Flows for the years ended December 31, 2017 and 2 |
|
| April 30, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 12, 2018 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Incorporation) (Comm |
|
| April 30, 2018 |
BOSTON THERAPEUTICS, INC. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION EXHIBIT 99.2 BOSTON THERAPEUTICS, INC. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined financial information is based on the historical financial statements of Boston Therapeutics, Inc. (the “Company”) and CureDM Group Holdings LLC (“CureDM”), after entering into an agreement on February 12, 2018 to acquire CureDM. The notes to the |
|
| March 27, 2018 |
BTHE / Boston Therapeutics Inc 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54586 BOSTON THERAPEUTICS, INC. |
|
| February 12, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 12, 2018 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 12, 2018 |
EX-10.1 2 s109010ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 CONTRIBUTION AGREEMENT Dated as of January 1, 2018 by and among Boston Therapeutics, Inc., a Delaware corporation and CureDM Group Holdings, LLC, a Delaware limited liability company and the Members of CureDM Group Holdings, LLC CONTRIBUTION AGREEMENT This Contribution Agreement (“Agreement”), dated as of 12:00 a.m. January 1, 2018 (the “Closin |
|
| February 12, 2018 |
Exhibit 10.2 EXECUTIVE RETENTION AGREEMENT This Executive Retention Agreement (the ?Agreement?) is made and entered into as of January 1, 2018 (the ?Effective Date?) by and between BOSTON THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and LORAINE UPHAM (the ?Executive?). Recitals: WHEREAS, the Executive is a key employee of the Company who possesses valuable proprietary knowledge of t |
|
| February 12, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Amendment No. 2 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2017 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Incorpor |
|
| February 9, 2018 |
BTHE / Boston Therapeutics Inc DEF 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (RULE 14C-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ? Preliminary Information Statement ? Definitive Information Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) BOSTON THERAPEUTICS, INC. (Name o |
|
| January 22, 2018 |
BTHE / Boston Therapeutics Inc PRE 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (RULE 14C-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ? Preliminary Information Statement ? Definitive Information Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) BOSTON THERAPEUTICS, INC. (Name o |
|
| November 13, 2017 |
BTHE / Boston Therapeutics Inc 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54586 BOSTON THERAPEUT |
|
| November 1, 2017 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Amendment No. 1 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2017 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Incorpor |
|
| August 22, 2017 |
Exhibit 4.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of , 2017, by and among Boston Therapeutics, Inc., a Delaware corporation (the ?Company?), and the purchasers identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions s |
|
| August 22, 2017 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2017 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 22, 2017 |
Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| August 22, 2017 |
Exhibit 4.2 Certificate of Designation of Preferences, Rights and Limitations OF SERIES A PREFERRED STOCK OF BOSTON THERAPEUTICS, INC. Pursuant to Section 151 of the Delaware General Corporation Law I, Carl W. Rausch, Chief Executive Officer of Boston Therapeutics, Inc., a corporation organized and existing under the Delaware General Corporation Law (the ?Corporation?), in accordance with the prov |
|
| August 10, 2017 |
BTHE / Boston Therapeutics Inc 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54586 BOSTON THERAPEUTICS, |
|
| June 19, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 16, 2017 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 11, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54586 BOSTON THERAPEUTICS, |
|
| May 2, 2017 |
Exhibit 4.3 THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER SUCH ACT AND/OR APPLICABLE STATE SECURITIES LAWS, OR AN OPINION |
|
| May 2, 2017 |
Exhibit 4.1 BOSTON THERAPEUTICS, INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (the ?Agreement?) is entered into by and between Boston Therapeutics, Inc., a Delaware corporation (the ?Company?), and the undersigned purchaser (the ?Purchaser?) as of the latest date set forth on the signature page hereto. NOW, THEREFORE, in consideration of the mutual covenants and other agre |
|
| May 2, 2017 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| May 2, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 26, 2017 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 28, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54586 BOSTON THERAPEUTICS, INC. |
|
| March 28, 2017 |
Exhibit 10.24 March 27, 2017 Boston Therapeutics, Inc. 354 Merrimack Street, #4 Lawrence, MA 01843 Re: Executive Employment Agreement dated August 12, 2016 between Boston Therapeutics, Inc. and Carl W. Rausch (the ?Agreement?) Gentlemen: Section 1(B) of the Agreement shall be amended and restated as follows: (B) Except for business travel by the Executive that may from time to time be necessary or |
|
| December 1, 2016 |
Boston Therapeutics BOSTON THERAPEUTICS, INC. 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 23, 2016 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 15, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 15, 2016 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 10, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54586 BOSTON THERAPEUT |
|
| October 13, 2016 |
BTHE / Boston Therapeutics Inc / Parnes Harold S - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Amendment No. 2 Under the Securities Exchange Act of 1934 Boston Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 05351T100 (CUSIP Number) Harold S. Parnes 1525 Voorhies Ave. Brooklyn, NY 11235 (347) 528-5297 (Name, Address and Telephone Number of Person A |
|
| September 20, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 15, 2016 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Incorporation) (Commi |
|
| September 14, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 11, 2016 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 15, 2016 |
Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (the "Agreement") is made and entered into as of the 12th day of August, 2016 (the "Start Date"), by and between Carl W. Rausch (the "Executive") and Boston Therapeutics, Inc., a Delaware corporation, currently headquartered at 233 Needham Street, Newton, MA 02464 (the "Company"). W I T N E S S E T H: WHEREAS, the Comp |
|
| August 15, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54586 BOSTON THERAPEUTICS, |
|
| August 15, 2016 |
Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (the "Agreement") is made and entered into as of the 12th day of August, 2016 (the "Start Date"), by and between Carl W. Rausch (the "Executive") and Boston Therapeutics, Inc., a Delaware corporation, currently headquartered at 233 Needham Street, Newton, MA 02464 (the "Company"). W I T N E S S E T H: WHEREAS, the Comp |
|
| August 15, 2016 |
Exhibit 4.1 BOSTON THERAPEUTICS, INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (the "Agreement") is entered into by and between Boston Therapeutics, Inc., a Delaware corporation (the "Company"), and the undersigned purchaser or purchasers (the "Purchaser", and collectively with other purchasers similarly situated, the "Purchasers") as of the latest date set forth on the sig |
|
| August 15, 2016 |
Exhibit 4.4 Boston Therapeutics Inc. 233 Needham Street Newton, MA 02464 August 12, 2016 CJY Holdings Limited 12 Repulse Bay Road Repulse Bay, Hong Kong Re: 10% Convertible Promissory Notes issued to CJY Holdings Limited by Boston Therapeutics Inc. in the aggregate principal amount of $1,702,000 (the "Notes") Gentlemen: Reference is hereby made to the Notes. All terms not defined below shall have |
|
| August 15, 2016 |
Exhibit 4.4 Boston Therapeutics Inc. 233 Needham Street Newton, MA 02464 August 12, 2016 CJY Holdings Limited 12 Repulse Bay Road Repulse Bay, Hong Kong Re: 10% Convertible Promissory Notes issued to CJY Holdings Limited by Boston Therapeutics Inc. in the aggregate principal amount of $1,702,000 (the "Notes") Gentlemen: Reference is hereby made to the Notes. All terms not defined below shall have |
|
| August 15, 2016 |
Exhibit 4.3 THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER SUCH ACT AND/OR APPLICABLE STATE SECURITIES LAWS, OR AN OPINION |
|
| August 15, 2016 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| August 15, 2016 |
Exhibit 4.3 THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER SUCH ACT AND/OR APPLICABLE STATE SECURITIES LAWS, OR AN OPINION |
|
| July 13, 2016 |
Boston Therapeutics BOSTON THERAPEUTICS RW BOSTON THERAPEUTICS, INC. 1750 Elm Street Manchester , NH 03104 July 12, 2016 VIA ELECTRONIC SUBMISSION Securities and Exchange Commission 100 F Street Washington, D.C. 20549 Re: Boston Therapeutics, Inc. (the "Company") Form S-1 Filed August 15, 2014 File No. 333-198198 Ladies and Gentlemen: We previously filed the above-referenced Form S-1 Registration Statement. Pursuant to Rule 477 promulgated |
|
| July 6, 2016 |
Exhibit 4.8 Boston Therapeutics Inc. 233 Needham Street Newton, MA 02464 June 28, 2016 CJY Holdings Limited 12 Repulse Bay Road Repulse Bay, Hong Kong Re: Securities Purchase Agreement dated September 24, 2015 (the ?SPA?) by and between Boston Therapeutics Inc. and CJY Holdings Limited, as amended Gentlemen: Reference is hereby made to the SPA. By executing this letter, the undersigned investor ag |
|
| July 6, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 24, 2015 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Incorporation) (Com |
|
| June 10, 2016 |
Boston Therapeutics BOSTON THERAPEUTICS 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 8, 2016 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 12, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 24, 2015 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Incorporation) (Com |
|
| May 12, 2016 |
Exhibit 4.7 Boston Therapeutics Inc. 233 Needham Street Newton, MA 02464 May 6, 2016 CJY Holdings Limited 12 Repulse Bay Road Repulse Bay, Hong Kong Re: Securities Purchase Agreement dated September 24, 2015 (the "SPA") by and between Boston Therapeutics Inc. and CJY Holdings Limited, as amended Gentlemen: Reference is hereby made to the SPA. By executing this letter, the undersigned investor agre |
|
| May 11, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54586 BOSTON THERAPEUTICS, |
|
| March 30, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54586 BOSTON THERAPEUTICS, INC. |
|
| March 22, 2016 |
Exhibit 4.6 Boston Therapeutics Inc. 1750 Elm Street Manchester, NH 03104 March 17, 2016 CJY Holdings Limited 12 Repulse Bay Road Repulse Bay, Hong Kong Re: Securities Purchase Agreement dated September 24, 2015 (the ?SPA?) by and between Boston Therapeutics Inc. and CJY Holdings Limited, as amended Gentlemen: Reference is hereby made to the SPA. By executing this letter, the undersigned investor |
|
| March 22, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 16, 2016 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 15, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Amendment No. 1 Under the Securities Exchange Act of 1934 Boston Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 05351T100 (CUSIP Number) Harold S. Parnes 1525 Voorhies Ave. Brooklyn, NY 11235 (347) 528-5297 (Name, Address and Telephone Number of Person |
|
| March 2, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 3 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 24, 2015 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Inc |
|
| March 2, 2016 |
EX-4.5 2 exh45.htm EXHIBIT 4.5 Exhibit 4.5 Boston Therapeutics Inc. 1750 Elm Street Manchester, NH 03104 March 1, 2016 CJY Holdings Limited 12 Repulse Bay Road Repulse Bay, Hong Kong Re: Securities Purchase Agreement dated September 24, 2015 (the "SPA") by and between Boston Therapeutics Inc. and CJY Holdings Limited, as amended Gentlemen: Reference is hereby made to the SPA. By executing this let |
|
| January 19, 2016 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 18, 2016 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 19, 2016 |
Exhibit 16.1 January 19, 2016 Securities and Exchange Commission Washington, D.C. 20549 Commissioners: We have read Boston Therapeutics, Inc.'s statements included under Item 4.01 of its Form 8-K filed on January 19, 2016 and we agree with such statements concerning our firm. /s/ RSM US LLP |
|
| December 10, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 24, 2015 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Incorporation) (Com |
|
| December 10, 2015 |
Exhibit 4.4 Boston Therapeutics Inc. 1750 Elm Street Manchester, NH 03104 November 30, 2015 CJY Holdings Limited 12 Repulse Bay Road Repulse Bay, Hong Kong Re: Securities Purchase Agreement dated September 24, 2015 (the "SPA") by and between Boston Therapeutics Inc. and CJY Holdings Limited, as amended Gentlemen: Reference is hereby made to the SPA. By executing this letter, the undersigned invest |
|
| November 20, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54586 BOSTON THERAPEUT |
|
| November 16, 2015 |
Boston Therapeutics BOSTON THERAPEUTICS NT 10-Q SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 000-54586 NOTIFICATION OF LATE FILING ( Check One ): ? Form 10-K ? Form 20-F ? Form 11-K T Form 10-Q ? Form N-SAR ? Form N-CAR For Period Ended: September 30, 2015 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transitio |
|
| November 12, 2015 |
Exhibit 10.1 WARRANT REPRICING AND EXERCISE AGREEMENT This WARRANT REPRICING AND EXERCISE AGREEMENT (this " Agreement") is made as of November 12, 2015, effective as of June 15, 2015, by and among Boston Therapeutics, Inc., a Delaware corporation (the " Company") and CJY Holdings Limited (the " Holder"). WHEREAS, the Holder is the listed owner of: (i) a Common Stock Purchase Warrant, dated August |
|
| November 12, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 12, 2015 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 30, 2015 |
exh41.htm Exhibit 4.1 Boston Therapeutics Inc. 303 East Wacker Drive, Suite 1040 Chicago, Illinois 60601 October 23, 2015 CJY Holdings Limited 12 Repulse Bay Road Repulse Bay, Hong Kong Re: Securities Purchase Agreement dated September 24, 2015 (the ?SPA?) by and between Boston Therapeutics Inc. and CJY Holdings Limited Gentlemen: Reference is hereby made to the SPA. By executing this letter, the |
|
| October 30, 2015 |
bostontherapeutics8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 24, 2015 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdicti |
|
| October 2, 2015 |
Boston Therapeutics BOSTON THERAPUTICS, INC. 8-K (Current Report/Significant Event) bostontheraputics8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 24, 2015 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction |
|
| October 2, 2015 |
exh101.htm EXHIBIT 10.1 Boston Therapeutics Inc. 303 East Wacker Drive, Suite 1040 Chicago, Illinois 60601 September 24, 2015 Typenex Co-Investment, LLC 303 East Wacker Drive, Suite 1040 Chicago, Illinois 60601 Attn: John M. Fife Re: Debt Settlement / Warrant Cancellation Dear Mr. Fife: Effective September 24, 2015, it is hereby acknowledged by Typenex Co-Investment, LLC, a Utah limited liability |
|
| October 2, 2015 |
exh42.htm EXHIBIT 4.2 NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR P |
|
| October 2, 2015 |
exh41.htm EXHIBIT 4.1 SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (this ?Agreement?), dated as of September 24, 2015, by and among Boston Therapeutics, Inc., a Delaware corporation, with headquarters located at 1750 Elm Street, Suite 103, Manchester, NH 03104 (the ?Company?), and the purchaser set forth on the signature page hereto (the ?Buyer?). WHEREAS: A. The Company and the Buy |
|
| September 28, 2015 |
Boston Therapeutics BOSTON THERAPEUTICS, INC. 8-K (Current Report/Significant Event) boston8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 28, 2015 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or Other Jurisdiction of Incorpor |
|
| September 28, 2015 |
exh991.htm Exhibit 99.1 Boston Therapeutics' BTI-320 in Clinical Trial Significantly Reduces Both Glucose and Fructose Levels in Blood Interim Clinical Results of BTI-320 on Post-Prandial Hyperglycemia in High-Risk Chinese Subjects with Pre-Diabetes. MANCHESTER, NH - (Marketwired) - 09/15/15 - Boston Therapeutics, Inc. (OTCQB: BTHE) today announced that its Hong Kong affiliate, Advance Pharmaceuti |
|
| September 24, 2015 |
BTHE / Boston Therapeutics Inc / VIS VIRES GROUP, INC. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1)* BOSTON THERAPEUTICS, INC. (Name of issuer) Common Stock, $0.001 value per share (Title of class of securities) 101150100 (CUSIP number) September 23, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| September 4, 2015 |
Boston Therapeutics BOSTON THERAPEUTICS, INC. 8-K (Current Report/Significant Event) boston8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 September 4, 2015 (September1, 2015) Date of Report (Date of earliest event reported) BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or other jurisdi |
|
| August 13, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54586 BOSTON THERAPEUTICS, |
|
| July 20, 2015 |
BTHE / Boston Therapeutics Inc / VIS VIRES GROUP, INC. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. )* BOSTON THERAPEUTICS, INC. (Name of issuer) Common Stock, $0.001 value per share (Title of class of securities) 101150100 (CUSIP number) July 20, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| July 16, 2015 |
Boston Therapeutics BOSTON THERAPEUTICS, INC. 8-K (Current Report/Significant Event) boston8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 16, 2015 (July 10, 2015) Date of Report (Date of earliest event reported) BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or other jurisdiction o |
|
| May 20, 2015 |
Exhibit 10.6 Securities Purchase Agreement This Securities Purchase Agreement (this ?Agreement?), dated as of March 12, 2015, is entered into by and between Boston Therapeutics, Inc., a Delaware corporation (?Company?), and Typenex Co-Investment, LLC, a Utah limited liability company, its successors and/or assigns (?Investor?). A. Company and Investor are executing and delivering this Agreement in |
|
| May 20, 2015 |
Exhibit 10.5 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| May 20, 2015 |
Exhibit 10.2 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE SOLD, TRANSFERRED, OR OTHERWISE DISPOSED OF IN THE ABSENCE OF SUCH REGISTRATION OR RECEIPT BY THE COMPANY OF AN OPINION OF COUNSEL IN THE FORM, SUBSTANCE AND SCOPE REASONABLY SATISFACTORY TO THE COMPANY THAT THIS NOTE MAY BE SOLD, TRANSFERRED, |
|
| May 20, 2015 |
Exhibit 10.7 CONVERTIBLE PROMISSORY NOTE Effective Date: March 12, 2015 U.S. $225,000.00 FOR VALUE RECEIVED, Boston Therapeutics, Inc., a Delaware corporation (?Borrower?), promises to pay to Typenex Co-Investment, LLC, a Utah limited liability company, or its successors or assigns (?Lender?), $225,000.00 and any interest, fees, charges, and late fees on the date that is eleven (11) months after t |
|
| May 20, 2015 |
Exhibit 10.4 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of March 16, 2015, by and between BOSTON THERAPEUTICS, INC., a Delaware corporation, with headquarters located at 1750 Elm Street - Suite 103, Manchester, NH 03104 (the ?Company?), and VIS VIRES GROUP, INC., a New York corporation, with its address at 111 Great Neck Road ? Suite 216, Great Nec |
|
| May 20, 2015 |
BOSTON THERAPEUTICS, INC. WARRANT TO PURCHASE SHARES OF COMMON STOCK Exhibit 10.8 THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS WARRANT UNDER SUCH ACT AND ANY APPLICABLE STAT |
|
| May 20, 2015 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of March 13, 2015, is entered into by and among Boston Therapeutics, Inc., a Delaware corporation (the ?Company?), and JDF Capital, Inc. (the ?Purchaser?). The Company and the Purchaser are sometimes referred to herein as a ?party? and collectively as the ?parties?. W I T N E S S E T H: WHEREA |
|
| May 20, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54586 BOSTON THERAPEUTICS, |
|
| May 20, 2015 |
Exhibit 10.3 BTHE $500,000 CONVERTIBLE NOTE Interest free if paid in full within 3 months FOR VALUE RECEIVED, Boston Therapeutics, Inc., a Delaware corporation (the ?Issuer? of this Security) with at least 38,556,508 common shares issued and outstanding, issues this Security and promises to pay to JMJ Financial, a Nevada sole proprietorship, or its Assignees (the ?Investor?) the Principal Sum alon |
|
| May 15, 2015 |
Boston Therapeutics BOSTON THERAPEUTICS, INC. NT 10-Q bostonnt10q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-54586 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): Form 10-K Form 20-F Form 11-K x Form 10-Q Form 10-D Form N-SAR Form N-CSR For Period Ended: March 31, 2015 Transition Report on Form 10-K Transition Report on Form 20-F Transition Report on Form 11-K Transition Report on |
|
| May 11, 2015 |
Boston Therapeutics BOSTON THERAPEUTICS, INC. S-1/A (NO. 5) bostons1a3.htm As filed with the Securities and Exchange Commission on May 11, 2015 Registration No. 333-198198 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 5 To FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 27-0801073 (State or jurisdiction of |
|
| April 28, 2015 |
As filed with the Securities and Exchange Commission on April 28, 2015 As filed with the Securities and Exchange Commission on April 28, 2015 Registration No. |
|
| April 28, 2015 |
Exhibit 10.13 SUBSCRIPTION AGREEMENT Boston Therapeutics, Inc. 1750 Elm Street, Suite 103 Manchester, NH 03104 Tel. (603) 935-9799 THIS SUBSCRIPTION AGREEMENT made this day of , 2015 by and between Boston Therapeutics, Inc., a Delaware corporation (hereinafter ? Company?), and the undersigned Subscriber (hereinafter ?Subscriber?), who, for and in consideration of the mutual promises and covenants |
|
| April 28, 2015 |
COMMON STOCK PURCHASE WARRANT BOSTON THERAPEUTICS, INC. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HY |
|
| April 1, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Boston Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 05351T100 (CUSIP Number) Kenneth A. Tassey, Jr. 226 Karatzas Avenue #309 Manchester, NH 03104 (978) 886-0421 (Name, Address and Telephone Number of Person Aut |
|
| March 27, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54586 BOSTON THERAPEUTICS, INC. |
|
| March 23, 2015 |
boston8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 23, 2015 (March 18, 2015) BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or other jurisdictio |
|
| March 19, 2015 |
Boston Therapeutics BOSTON THERAPEUTICS, INC. 8-K (Current Report/Significant Event) boston8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 19, 2015 (March 13, 2015) BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or other jurisdictio |
|
| February 20, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Boston Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 05351T100 (CUSIP Number) Harold S. Parnes 1525 Voorhies Ave. Brooklyn, NY 11235 (347) 528-5297 (Name, Address and Telephone Number of Person Authorized to Rec |
|
| February 11, 2015 |
BTHE / Boston Therapeutics Inc S-1/A - - BOSTON THERAPEUTICS, INC. S-1/A As filed with the Securities and Exchange Commission on February 11, 2015 Registration No. |
|
| February 9, 2015 |
BTHE / Boston Therapeutics Inc S-1/A - - BOSTON THERAPEUTICS, INC. S-1/A As filed with the Securities and Exchange Commission on February 9, 2015 Registration No. |
|
| November 13, 2014 |
BTHE / Boston Therapeutics Inc S-1/A - - BOSTON THERAPEUTICS, INC. S-1/A As filed with the Securities and Exchange Commission on November 13, 2014 Registration No. |
|
| November 7, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54586 BOSTON THERAPEUT |
|
| November 7, 2014 |
Exhibit 10.1 MARKETING AGREEMENT THIS MARKETING AGREEMENT (the ?Agreement?), is entered into as of May 14, 2014 (the ?Effective Date?) by and between: (1) Boston Therapeutics, Inc., a company incorporated under the laws of the State of Delaware, USA, with offices at 1750 Elm Street, Suite 103, Manchester, NH 03101, USA (?BTI?); and (2) Benchworks SD LLC., with offices at 1512 Spruce St, Philadelph |
|
| October 14, 2014 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 14, 2014 (October 9, 2014) BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or other jurisdiction of (Comm |
|
| October 14, 2014 |
Boston Therapeutics Reports Topline U.S.-Based Phase IIb Study Results of BTI-320 in Patients with Type 2 Diabetes Results from Four Trials to Support Tests Methods and Dose Configuration for the Phase III Study Slated for 2015 MANCHESTER, NH – October 9, 2014 -Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to mana |
|
| October 1, 2014 |
Exhibit 99.1 Boston Therapeutics Appoints Jan Brinkman, M.D., Ph.D. and Alan M. Hoberman, Ph.D. to Board of Directors Increases Total Number of Board Members to Eight MANCHESTER, NH – October 1, 2014 - Boston Therapeutics, Inc. (OTCQB: BTHE) (“Boston Therapeutics” or “the Company”), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, has appointed Jan Brin |
|
| October 1, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 October 1, 2014 (September 25, 2014) Date of Report (Date of earliest event reported) BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or other jurisdiction of (Com |
|
| September 22, 2014 |
Boston Therapeutics Signs Clinical Trial Agreement With Prestigious Joslin Diabetes Center for Phase III Study of BTI-320 360 Patients to Be Enrolled in Phase III Study at 10 Sites in Four Countries; BTI-320, a Non-Systemic Chewable Tablet, Represents a New Generation of Alpha Glycosidase Inhibitors MANCHESTER, NH - (Marketwired - September 22, 2014) - Boston Therapeutics, Inc. |
|
| September 22, 2014 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: September 22, 2014 (Date of earliest event reported) Boston Therapeutics, Inc. (Exact name of registrant as specified in its charter) NH (State or other jurisdiction of incorporation) 000-54586 (Commission File Number |
|
| August 15, 2014 |
As filed with the Securities and Exchange Commission on August 15, 2014 As filed with the Securities and Exchange Commission on August 15, 2014 Registration No. |
|
| August 8, 2014 |
SEPARATION AGREEMENT AND GENERAL RELEASE Exhibit 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (the ?Agreement?) is made and entered into by Kenneth A. Tassey, Jr. for himself, his heirs, dependents, beneficiaries, executors, administrators, successors, assigns and anyone acting on his behalf (collectively referred to in this Agreement as ?Executive?) and Boston Therapeutics Inc. and its affi |
|
| August 8, 2014 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54586 BOSTON THERAPEUTICS, |
|
| July 3, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 3, 2014 (June 30, 2014) Date of Report (Date of earliest event reported) BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or other jurisdiction of (Commission |
|
| May 21, 2014 |
Exhibit 99.1 Boston Therapeutics Announces Strategic Marketing Agreement with Benchworks SD Aimed At Growing Sales of SUGARDOWN® Benchworks to Develop & Implement Strategies to Maximize Brand Awareness by Positioning SUGARDOWN® as an Adjunct to Diet and Exercise to Better Manage Blood Sugar MANCHESTER, NH - May 20, 2014 – Boston Therapeutics, Inc. (OTCQB: BTHE) a leading developer of compounds tha |
|
| May 21, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 21, 2014 (May 14, 2014) Date of Report (Date of earliest event reported) BOSTON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-54586 27-0801073 (State or other jurisdiction of (Commission F |
|
| May 13, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54586 BOSTON THERAPEUTICS, |
|
| April 17, 2014 |
AMENDED AND RESTATED BOSTON THERAPEUTICS, INC. 2010 STOCK PLAN Exhibit 10.1 AMENDED AND RESTATED BOSTON THERAPEUTICS, INC. 2010 STOCK PLAN 1. Establishment, Purpose and Term of Plan. 1.1 Establishment. The Boston Therapeutics, Inc. 2010 Stock Plan (formerly, Avanyx Therapeutics, Inc. 2010 Stock Plan (the “Plan”) was originally adopted by the Company effective as of June 16, 2010 (the “Effective Date”) and, subject to shareholder approval, was amended and rest |
|
| April 17, 2014 |
- BOSTON THERAPEUTICS, INC. S-8 As filed with the Securities and Exchange Commission on April 17, 2014 Registration No. |
